文献速递痛风与晶体性关节病

痛风患者启动降尿酸治疗时联用或不联用秋水仙碱预防发作的心血管事件:基于初级保健、住院和死亡数据链接的回顾性新用药者队列研究

Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.
PubMed 文献 · Lancet Rheumatol · 2024-12-18

该回顾性新用药者队列研究利用英国初级保健数据库链接住院和死亡记录,纳入99 800例首次启动降尿酸治疗的痛风患者,比较同日处方秋水仙碱预防(≥21天)与未处方任何痛风发作预防者的心血管事件风险。意向性治疗分析中,秋水仙碱预防组加权心血管事件发生率为28.8/1000人年,无预防组为35.3/1000人年,加权风险差-6.5(95%CI -9.4至-3.6)/1000人年,加权HR 0.82(0.69-0.94)。作者认为秋水仙碱预防与心血管事件风险降低相关,为使用秋水仙碱预防痛风发作提供了额外论据。

要点

  • 首次启动降尿酸治疗的痛风患者中,16.1%同日处方秋水仙碱预防(≥21天)。
  • 秋水仙碱预防组加权心血管事件率28.8/1000人年,无预防组35.3/1000人年。
  • 加权HR 0.82(95%CI 0.69-0.94),加权风险差-6.5(95%CI -9.4至-3.6)/1000人年。

核心结论

  • 在启动降尿酸治疗的痛风患者中,处方秋水仙碱预防者较未预防者心血管事件风险降低。
  • 作者认为这些发现为使用秋水仙碱预防痛风发作提供了额外论据。

研究设计与样本

  • 回顾性新用药者队列研究,使用英国临床实践研究数据链Aurum初级保健数据库链接住院和死亡记录。
  • 纳入99 800例首次启动降尿酸治疗的痛风患者,比较同日处方秋水仙碱预防(定义为处方≥21天)与未处方任何痛风发作预防者。
  • 采用倾向评分重叠加权平衡组间协变量,使用Cox回归进行意向性治疗和符合方案分析,后者采用逆概率删失加权。
  • 主要结局为启动降尿酸治疗后180天内致死性和非致死性心肌梗死或卒中的复合终点,无论既往有无心血管事件。

主要发现

  • 99 800例患者中,25 511例(25.6%)为女性,74 289例(74.4%)为男性,84 928例(85.1%)为白人,平均年龄62.8岁(SD 15.5)。
  • 4 063例(4.1%)患者有既往心血管事件,16 028例(16.1%)患者处方了秋水仙碱预防。
  • 意向性治疗分析中,秋水仙碱预防组加权心血管事件率为28.8/1000人年(95%CI 25.2-33.2),无预防组为35.3/1000人年(95%CI 33.0-37.9)。
  • 加权风险差为-6.5(95%CI -9.4至-3.6)/1000人年,加权HR为0.82(95%CI 0.69-0.94)。
  • 不同分析方法、分层分析和次要结局的结果相似。

关键数值与推荐

  • 秋水仙碱预防定义为与降尿酸治疗同日处方且处方≥21天。
  • 主要结局为启动降尿酸治疗后180天内致死性和非致死性心肌梗死或卒中的复合终点。
  • 意向性治疗分析加权HR 0.82(95%CI 0.69-0.94),加权风险差-6.5(95%CI -9.4至-3.6)/1000人年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Initiating urate-lowering therapy can trigger gout flares. Gout flares have been associated with a temporally increased risk of cardiovascular events. Therefore, we aimed to estimate the risk of cardiovascular events in patients with gout initiating urate-lowering therapy with flare prophylaxis using colchicine (the drug recommended for gout flare prohphylaxis by many international societies) compared with no prophylaxis. METHODS: We did a retrospective new-user cohort study using data from the Clinical Practice Research Datalink Aurum, an English primary-care database linked to hospitalisation and mortality records. People with gout initiating urate-lowering therapy for the first time were eligible for inclusion. We compared people prescribed flare prophylaxis with colchicine with those not prescribed any gout flare prophylaxis. Colchicine prophylaxis (defined as prescription for ≥21 days) prescribed on the same date as urate-lowering therapy was the exposure of interest. A composite of fatal and non-fatal myocardial infarction or stroke within 180 days after urate-lowering therapy initiation regardless of any previous cardiovascular event was the primary outcome. Propensity score overlap weighting was used to balance covariates across study groups. We used Cox regression and performed intention-to-treat and per-protocol analyses, the latter with an inverse probability of censoring weighting. The association was measured using hazard ratio and risk difference with 95% CIs. Members of The UK Gout Society were involved in prioritising the research question. FINDINGS: Of the 111 460 patients eligible for the study, 99 800 patients with gout initiating urate-lowering therapy were included. 25 511 (25·6%) of 99 800 patients were female, 74 289 (74·4%) were male, 84 928 (85·1%) patients were White and the mean age was 62·8 years (SD 15·5). 4063 (4·1%) patients had previous cardiovascular events and 16 028 (16·1%) patients were prescribed colchicine prophylaxis. Patients with colchicine prophylaxis had significantly lower risk of cardiovascular events compared with those without prophylaxis. The weighted rates of cardiovascular events were 28·8 per 1000 person-years (95% CI 25·2 to 33·2) in patients with colchicine prophylaxis and 35·3 per 1000 person-years (33·0 to 37·9) in those without prophylaxis (weighted rate difference -6·5 [95% CI -9·4 to -3·6] per 1000 person-years and weighted hazard ratio 0·82 [0·69-0·94]) in the intention-to-treat analysis. Findings were similar across analytical approaches, stratified analyses, and for secondary outcomes. INTERPRETATION: In patients with gout initiating urate-lowering therapy, the risk of cardiovascular events was reduced in those prescribed colchicine prophylaxis compared with no prophylaxis. These findings provide an additional argument for using colchicine for gout flare prophylaxis. FUNDING: Foundation for Research in Rheumatology.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Cipolletta E, Nakafero G, McCormick N, et al. Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol. 2024. PMID: 39708831. doi:10.1016/S2665-9913(24)00248-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。